1854 ET - Hims & Hers Health guided for 2Q revenue of $530 million to $550 million, down from 1Q and below analyst expectations, but executives say during the company's earnings call the sequential sales drop will be a one-time event. The executives say the guidance reflects a transition of subscribers previously on commercially-available semaglutide--which the company previously offered amid a shortage of branded treatments Wegovy and Ozempic--to alternatives on the Hims platform or other platforms. The executives say they expect the transition to be complete by the end of the 2Q, and expect to continue growing revenue from there on out in the remainder of the year. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
May 05, 2025 18:54 ET (22:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.